Cullinan Therapeutics
Cullinan Therapeutics
CGEM
NASDAQ
8.77
USD
-1.68%
About
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases.
Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies.
CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 459.7K |
| Three Month Average Volume | 16.7M |
| High Low | |
| Fifty-Two Week High | 30.1886 USD |
| Fifty-Two Week Low | 7.64 USD |
| Fifty-Two Week High Date | 07 May 2024 |
| Fifty-Two Week Low Date | 12 Dec 2023 |
| Price and Volume | |
| Current Price | 19.6 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | 4.46% |
| Thirteen Week Relative Price Change | -22.07% |
| Twenty-Six Week Relative Price Change | -3.70% |
| Fifty-Two Week Relative Price Change | 51.13% |
| Year-to-Date Relative Price Change | 62.43% |
| Price Change | |
| One Day Price Change | 3.92% |
| Thirteen Week Price Change | -16.60% |
| Twenty-Six Week Price Change | 5.89% |
| Five Day Price Change | 8.71% |
| Fifty-Two Week Price Change | 89.37% |
| Year-to-Date Price Change | 92.35% |
| Month-to-Date Price Change | 1.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 10.57581 USD |
| Book Value Per Share (Most Recent Quarter) | 11.33925 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 10.57581 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 11.33925 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.98665 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.68621 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.10002 USD |
| Normalized (Last Fiscal Year) | -3.67933 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.68621 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.10002 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.68621 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.10002 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 10.88732 USD |
| Cash Per Share (Most Recent Quarter) | 11.44766 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.72542 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.13287 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.76264 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,881 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -878.97% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -1,039.96% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -1,026.78% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 67.45% |
| Tangible Book Value (5 Year) | 68.65% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -4.44% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 5.32% |
| EPS Change (Trailing Twelve Months) | 7.74% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -662,495,000 |
| Net Debt (Last Fiscal Year) | -467,067,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 8 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 4 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 17 |
| Current Ratio (Most Recent Quarter) | 29 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -134,483,000 |
| Free Cash Flow (Trailing Twelve Months) | -126,810,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -29.68% |
| Return on Assets (Trailing Twelve Months) | -23.96% |
| Return on Assets (5 Year) | -12.37% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -30.98% |
| Return on Equity (Trailing Twelve Months) | -24.60% |
| Return on Equity (5 Year) | -17.01% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.19% |
| Return on Investment (Trailing Twelve Months) | -24.85% |
| Return on Investment (5 Year) | -12.93% |